Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q1 2026 · 10-Q
Revenue—
Net Income$38.31M$38.31MN/M vs Q1 2025 EPS Diluted$0.91$0.91N/M vs Q1 2025 Operating Income-$3,659,000N/M Operating Cash Flow-$2,915,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,920,000N/M ended Mar 31, 2026 · filed May 19, 2026 · 49 d after period end